Precision treatment of lung cancer at 2019 European Lung Cancer Conference: Advances and prospects / 医学研究生学报

ABSTRACT

The scientificity and value of precision medicine are adequately reflected in the diagnosis and treatment of lung cancer. Numerous drugs for lung cancer are being developed and the therapeutic data constantly updated. Study of the targeted molecular therapy is concentrated on the optimal selection, combination and administration of drugs for common mutation targets after drug resistance, and that of the immunotherapy on more precise stratification. The clinical data on the targeted therapy and immunotherapy for lung cancer were updated at the European Conference on Lung Cancer (ECLC) in 2019. This paper focuses on the data from the ECLC on the studies of the targeted therapy for lung cancer, relating the epidermal growth factor receptor, anaplastic lymphoma kinase, ROS1 fusion, and immunotherapy for elderly patients with lung cancer as well as for those with different PDL1 expression levels, aiming to provide some reference for more scientific, standardized and precise administration of drugs in clinical practice.